|
Symptom organ class | Patients, (%) | Antibiotics | Frequency of ADRs, (%) |
|
Skin and subcutaneous tissue disorders | 576 (45.1) | Quinolone Penicillin 3rd cephalosporin | 98 (17.0) 88 (15.3) 86 (14.9) |
|
Gastrointestinal disorders | 416 (32.6) | 3rd cephalosporin Quinolone Penicillin | 79 (19.0) 66 (15.9) 61 (14.7) |
|
Allergic disorders | 125 (9.8) | Glycopeptide Penicillin 3rd cephalosporin | 24 (19.2) 22 (17.6) 18 (14.4) |
|
Nervous system disorders | 91 (7.1) | Quinolone 3rd cephalosporin 2nd cephalosporin | 16 (17.6) 14 (15.4) 12 (13.2) |
|
Blood and lymphatic system disorders | 68 (5.3) | Penicillin Glycopeptide 3rd cephalosporin | 20 (29.4) 14 (20.6) 8 (11.8) |
|
Cardiac disorders | 43 (3.4) | Quinolone 3rd cephalosporin 2nd cephalosporin | 8 (18.6) 7 (16.3) 7 (16.3) |
|
General disorders and administration site conditions | 31 (2.4) | Quinolone Antiviral agent | 11 (61.1) 2 (11.1) |
|
Renal and urinary disorders | 24 (1.9) | Glycopeptide Penicillin Antifungal agent | 5 (20.8) 5 (20.8) 3 (12.5) |
|
Respiratory, thoracic, and mediastinal disorders | 23 (1.8) | 3rd cephalosporin Antifungal agent Penicillin | 6 (26.1) 5 (21.7) 4 (17.4) |
|
Hepatobiliary disorders | 23 (1.8) | Anti-TB medication Penicillin Carbapenem | 6 (26.1) 3 (13.0) 3 (13.0) |
|
Eye disorder | 5 (0.4) | Anti-TB medication Penicillin | 4 (80.0) 1 (20.0) |
|
Psychiatric disorders | 4 (0.3) | 2nd cephalosporin Carbapenem Quinolone | 2 (50.0) 1 (25.0) 1 (25.0) |
|
Musculoskeletal and connective tissue disorders | 2 (0.2) | Penicillin Antifungal agent | 1 (50.0) 1 (50.0) |
|